[A case of adrenocortical carcinoma with Cushing's syndrome presenting unusual urinary 17-ketosteroid fractionation]. 1984

H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki

A patient with adrenocortical carcinoma with Cushing's syndrome is presented. This case seems to be most characterized by its very unusual urinary 17-ketosteroid (KS) fractionation, since markedly increased etiocholanolone was not accompanied by increments of either DHEA or androsterone. Determination of the plasma adrenocorticosteroids of the patient revealed normal DHEA and DHEA-S levels, moderately increased 17-OH-pregnenolone, and markedly increased 11-deoxycortisol. Therefore, it seems plausible that the unique 17-KS fractionation of this patient would have ensued as a result of remarkably decreased C17-20 lyase activity sufficient to nullify the increased 17-OH-pregnenolone and that markedly increased etiocholanolone might have been converted from 11-deoxycortisol.

UI MeSH Term Description Entries
D008297 Male Males
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D003687 Dehydroepiandrosterone A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. Dehydroisoandrosterone,Prasterone,5-Androsten-3-beta-hydroxy-17-one,5-Androsten-3-ol-17-one,Androstenolone,DHEA,Prasterone, 3 alpha-Isomer,5 Androsten 3 beta hydroxy 17 one,5 Androsten 3 ol 17 one,Prasterone, 3 alpha Isomer
D005043 Etiocholanolone The 5-beta-reduced isomer of ANDROSTERONE. Etiocholanolone is a major metabolite of TESTOSTERONE and ANDROSTENEDIONE in many mammalian species including humans. It is excreted in the URINE. 3-alpha-Hydroxy-5-beta-Androstan-17-One,5-beta-Androsterone,3 alpha Hydroxy 5 beta Androstan 17 One,5 beta Androsterone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000306 Adrenal Cortex Neoplasms Tumors or cancers of the ADRENAL CORTEX. Adrenocortical Cancer,Cancer of Adrenal Cortex,Adrenal Cortex Cancer,Cancer of the Adrenal Cortex,Neoplasms, Adrenal Cortex,Adrenal Cortex Cancers,Adrenal Cortex Neoplasm,Adrenocortical Cancers,Cancer, Adrenal Cortex,Cancer, Adrenocortical,Cancers, Adrenal Cortex,Cancers, Adrenocortical,Neoplasm, Adrenal Cortex
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000738 Androsterone A metabolite of TESTOSTERONE or ANDROSTENEDIONE with a 3-alpha-hydroxyl group and without the double bond. The 3-beta hydroxyl isomer is epiandrosterone. 3-alpha-Hydroxy-5-alpha-Androstan-17-One,5 alpha-Androstan-3 alpha-ol-17-one,Epiandrosterone,3 alpha Hydroxy 5 alpha Androstan 17 One,5 alpha Androstan 3 alpha ol 17 one
D015065 17-Hydroxycorticosteroids A group of hydroxycorticosteroids bearing a hydroxy group at the 17-position. Urinary excretion of these compounds is used as an index of adrenal function. They are used systemically in the free alcohol form, but with esterification of the hydroxy groups, topical effectiveness is increased. 17 Hydroxycorticosteroids

Related Publications

H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
April 1957, Acta endocrinologica,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
July 2008, Journal of medical case reports,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
May 1969, The British journal of psychiatry : the journal of mental science,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
October 1961, Nordisk medicin,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
April 1964, Kiserletes orvostudomany,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
January 1965, Nihon Naibunpi Gakkai zasshi,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
February 1970, Hinyokika kiyo. Acta urologica Japonica,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
April 2006, Endocrine journal,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
November 2011, Japanese journal of clinical oncology,
H Watanobe, and K Kannari, and S Murabayashi, and K Kimura, and K Takebe, and M Ojima, and K Suzuki
September 1980, The Tohoku journal of experimental medicine,
Copied contents to your clipboard!